|
English
|
正體中文
|
简体中文
|
2818688
|
|
???header.visitor??? :
28252927
???header.onlineuser??? :
771
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"dearden s"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
|
Shepherd F.A.;Cantarini M;Patel S;Dearden S;Weston S;Hodge R;Yu K;Thress K.S;J?nne P.A;Chih-Hsin Yang;Jenkins S; Jenkins S; Chih-Hsin CHIH-HSIN YANG; Jänne P.A; Thress K.S; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd F.A. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
|
Shepherd F.A.;Cantarini M;Patel S;Dearden S;Weston S;Hodge R;Yu K;Thress K.S;J?nne P.A;Chih-Hsin Yang;Jenkins S; Jenkins S; Chih-Hsin CHIH-HSIN YANG; Jänne P.A; Thress K.S; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd F.A. |
| 國立成功大學 |
2019 |
Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus Comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non–small cell lung cancer
|
Gray, J.E.;Okamoto, I.;Sriuranpong, V.;Vansteenkiste, J.;Imamura, F.;Lee, J.S.;Pang, Y.-K.;Cobo, M.;Kasahara, Kasahara K.;Cheng, Y.;Nogami, Nogami N.;Cho, E.K.;Su, W.C.;Zhang, G.;Huang, X.;Li-Sucholeiki, X.;Lentrichia, B.;Dearden, S.;Jenkins, S.;Saggese, M.;Rukazenkov, Y.;Ramalingam, S.S. |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
